Breast cancer is one of the most survivable cancers. The overall 5-year relative survival rate for women diagnosed with breast cancer in the United States is 91.7%, based on cases diagnosed between 2015 and 2021. That means more than 9 in 10 women are alive five years after diagnosis. But that single number masks a wide range of outcomes depending on how early the cancer is caught, what type it is, and other individual factors.
Stage at Diagnosis Is the Biggest Factor
The stage at which breast cancer is found has an enormous effect on survival. Nearly two-thirds of women (64%) are diagnosed when the cancer is still localized, meaning it hasn’t spread beyond the breast. For these women, the 5-year relative survival rate is effectively 100%.
About 28% of cases are diagnosed at a regional stage, where the cancer has spread to nearby lymph nodes but not to distant organs. Survival at this stage drops to 87.2%, which is still quite favorable. The 6% of women diagnosed with distant (metastatic) disease face a much tougher outlook, with a 5-year survival rate of 32.6%.
This is why screening matters so much. Regular mammography has been shown to reduce breast cancer mortality by 15 to 30%. The American Cancer Society recommends women ages 45 to 54 get mammograms every year, with the option to start at 40. Women 55 and older can switch to every other year or continue annually.
How Cancer Subtype Affects Survival
Not all breast cancers behave the same way. Doctors classify tumors by whether they respond to hormones and by a protein called HER2. These molecular subtypes carry meaningfully different survival rates.
The most common type, hormone receptor-positive/HER2-negative, has the best overall prognosis at 95.6% five-year survival. Tumors that are both hormone receptor-positive and HER2-positive come in at 91.8%. HER2-positive tumors that don’t respond to hormones have an 86.5% survival rate. Triple-negative breast cancer, which doesn’t respond to hormones or HER2-targeted therapies, has the lowest five-year survival at 78.4%.
These subtypes also affect when a cancer is most likely to come back. Triple-negative breast cancer tends to recur early, with a sharp peak around 18 months after treatment. About 92% of triple-negative recurrences happen within the first five years, and after that the risk drops dramatically. Hormone receptor-positive cancers behave differently: they have a lower yearly recurrence risk, but that risk persists steadily over many years. Among recurrences that happen after the five-year mark, nearly two-thirds involve hormone receptor-positive subtypes.
Lymph Node Involvement
When breast cancer spreads to nearby lymph nodes, it signals a more advanced disease. Survival rates can be up to 40% lower in women with positive lymph nodes compared to those without. The more nodes involved, the worse the outlook. Women with four to nine positive nodes face roughly double the risk of dying from their cancer compared to women with one to three. Ten or more positive nodes carries a similar increase.
Racial Disparities in Outcomes
Survival statistics are not equal across racial groups. Black women are less likely to be diagnosed at stage I than white women (37% vs. 51%) and are nearly twice as likely to die even when their tumors are small (2 cm or less). This disparity persists even after accounting for triple-negative breast cancer, which is more common in Black women. Under age 50, Black women face an 88% higher rate of breast cancer death compared to white women of the same age.
Among all women who die of breast cancer, those from minority groups are significantly more likely to die before age 50. Hispanic women have a 164% higher risk of early death, Asian American/Pacific Islander women 129% higher, and Black women 111% higher, all compared to white women. These gaps reflect a combination of later diagnosis, differences in tumor biology, and unequal access to care.
Long-Term Survival Beyond Five Years
Five-year survival is the standard benchmark, but many people want to know what happens further out. In studies tracking women over longer periods, 10-year overall survival is around 71% and 15-year survival is about 70%. The relatively small drop between 10 and 15 years shows that women who reach the decade mark have a good chance of continued survival. However, these longer-term numbers vary considerably by subtype and stage, and they reflect outcomes from treatments available years ago. Women diagnosed today generally have access to more effective therapies.
Metastatic Breast Cancer Is Improving
The outlook for women diagnosed with stage IV disease, while still serious, has improved meaningfully. Women diagnosed with metastatic breast cancer in 2000 lived an average of 1.9 years after diagnosis. By 2019, that number had climbed to 3.2 years. Newer targeted therapies and immunotherapies continue to push these numbers upward, and some women with metastatic disease now live well beyond five years, particularly those with hormone receptor-positive or HER2-positive tumors.
Men Face a Different Picture
Breast cancer in men is rare, accounting for less than 1% of all cases, but it tends to have worse outcomes. The five-year overall survival rate for men with breast cancer is 77.6%, compared to 86.4% for women. Men are more often diagnosed at later stages, partly because breast cancer isn’t on most men’s radar and screening isn’t routine for them.